NEW YORK (360Dx) – Diagnostic company executives are eagerly anticipating the repeal, which could come as early as this year, of a 2.3 percent excise tax on medical devices established in 2010 as part of the Affordable Care Act.

The tax was levied against all FDA-listed diagnostic tests and devices intended to diagnose a disease or condition and went into effect in 2013; the tax did not apply to OTC products, such as pregnancy tests. It was imposed on device and diagnostic sales between 2013 and 2015 but has been suspended twice since then.